[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5850 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 5850

 To nullify modifications made by the Food and Drug Administration on 
 January 3, 2023, to the risk evaluation and mitigation strategy under 
 section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
            355-1) for mifepristone, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 29, 2023

Mr. Mann (for himself and Mr. Moolenaar) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To nullify modifications made by the Food and Drug Administration on 
 January 3, 2023, to the risk evaluation and mitigation strategy under 
 section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
            355-1) for mifepristone, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. NULLIFICATION OF REMS MODIFICATIONS FOR MIFEPRISTONE; NO 
              FEDERAL FUNDING TO IMPLEMENT REMS FOR MIFEPRISTONE.

    (a) In General.--The modifications made by the Food and Drug 
Administration on January 3, 2023, to the risk evaluation and 
mitigation strategy under section 505-1 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355-1) for mifepristone are hereby nullified.
    (b) Prohibition on Federal Funds.--No Federal funds may be used to 
establish, implement, or enforce--
            (1) any provision of a risk evaluation and mitigation 
        strategy under section 505-1 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 355-1) for mifepristone that is 
        substantially similar to any of the modifications nullified by 
        subsection (a); or
            (2) any non-enforcement or enforcement discretion policy 
        for any provision of a risk evaluation and mitigation strategy 
        under such section for mifepristone.
                                 <all>